Some nonsteroidal anti-inflammatory drugs (NSAIDs) have come under fire
recently because of their link to increased risk of myocardial infarction
and stroke. But increasing evidence suggests the value of some of these drugs
for certain cancer patients may outweigh such risks, according to findings
presented at the annual meeting of the American Association for Cancer Research,
held in Anaheim in April.
One new study highlighted at the conference revealed the effects of
the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib on gene expression in the
colon of individuals genetically at risk for hereditary nonpolyposis colon
cancer. Previously reported epidemiological studies have shown that COX-2
inhibitors suppress colorectal carcinogenesis and reduce the risk of death
from colorectal cancer, and these new results may point to the mechanisms
by which this is accomplished.
Hampton T. NSAID Studies Abound in Cancer Research. JAMA. 2005;293(21):2579-2580. doi:10.1001/jama.293.21.2579